Item 2.02 Results of Operations and Financial Condition.

On July 29, 2021, Agios Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the quarter ended June 30, 2021 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On July 27, 2021, Christopher Bowden notified the Company of his intention to resign as chief medical officer of the Company, effective September 1, 2021. Beginning October 16, 2021, Dr. Bowden will transition from a full-time employee to a part-time employee, for which he will be compensated at fifty percent (50%) of his 2021 salary as described in the Company's Proxy Statement for the 2021 Annual Meeting of Stockholders. Dr. Bowden will be eligible to receive an annual bonus under the Company's annual performance-based cash incentive program for the fiscal year 2021 based on his full-time 2021 annual base salary.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit No.       Description

99.1                Press release issued July 29, 2021.

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses